These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32597142)

  • 21. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicinal use of cannabis based products and cannabinoids.
    Freeman TP; Hindocha C; Green SF; Bloomfield MAP
    BMJ; 2019 Apr; 365():l1141. PubMed ID: 30948383
    [No Abstract]   [Full Text] [Related]  

  • 24. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory status of medicinal products for human beings in the European Union. The role of generic products.
    Minghetti P
    Pharmacol Res; 1996; 34(1-2):3-7. PubMed ID: 8981548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of immunological veterinary medicinal products in the European Union.
    Brunko P
    Rev Sci Tech; 1995 Dec; 14(4):1133-41. PubMed ID: 8639951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review.
    Alves VL; Gonçalves JL; Aguiar J; Teixeira HM; Câmara JS
    Crit Rev Toxicol; 2020 May; 50(5):359-382. PubMed ID: 32530350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.
    Orsolini L; Chiappini S; Volpe U; Berardis D; Latini R; Papanti GD; Corkery AJM
    Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31450833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Public health issue brief: medical marijuana: year end report-2004.
    Varma P
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-9. PubMed ID: 15765574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible therapeutic applications of cannabis in the neuropsychopharmacology field.
    Fernández-Ruiz J; Galve-Roperh I; Sagredo O; Guzmán M
    Eur Neuropsychopharmacol; 2020 Jul; 36():217-234. PubMed ID: 32057592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discrimination of legal and illegal Cannabis spp. according to European legislation using near infrared spectroscopy and chemometrics.
    Duchateau C; Kauffmann JM; Canfyn M; Stévigny C; De Braekeleer K; Deconinck E
    Drug Test Anal; 2020 Sep; 12(9):1309-1319. PubMed ID: 32453873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia.
    Lancaster K; Seear K; Ritter A
    Int J Drug Policy; 2017 Nov; 49():117-125. PubMed ID: 28886887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use.
    Hall W; Stjepanović D; Caulkins J; Lynskey M; Leung J; Campbell G; Degenhardt L
    Lancet; 2019 Oct; 394(10208):1580-1590. PubMed ID: 31657733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomedicines in the EU-Regulatory Overview.
    Pita R; Ehmann F; Papaluca M
    AAPS J; 2016 Nov; 18(6):1576-1582. PubMed ID: 27527889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC-MS and LC-HRMS (q-exactive orbitrap®) approach.
    Calvi L; Pentimalli D; Panseri S; Giupponi L; Gelmini F; Beretta G; Vitali D; Bruno M; Zilio E; Pavlovic R; Giorgi A
    J Pharm Biomed Anal; 2018 Feb; 150():208-219. PubMed ID: 29247961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Requirements on efficacy of herbal medicinal products.
    Claeson P
    J Ethnopharmacol; 2014 Dec; 158 Pt B():463-6. PubMed ID: 25043782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug safety in the European community.
    Sauer F
    Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulations applicable to plant food supplements and related products in the European Union.
    Silano V; Coppens P; Larrañaga-Guetaria A; Minghetti P; Roth-Ehrang R
    Food Funct; 2011 Dec; 2(12):710-9. PubMed ID: 21997496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.